Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y

Physiology and Behavior

Volumn 107, Issue 5, 2012, Pages 699-710

  Bowers, Mallory E ^a   Choi, Dennis C ^a   Ressler, Kerry J ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Amygdala; Cannabinoid; CCK; Endorphin; Enkephalin; Extinction; MOR; Nociceptin; NPY; Opioid; Panic; Phobia; PTSD

Indexed keywords

ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; DELTA OPIATE RECEPTOR; DYNORPHIN; ENDOMORPHIN 1; ENDORPHIN; ENKEPHALIN; KAPPA OPIATE RECEPTOR; MESSENGER RNA; MU OPIATE RECEPTOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; NOCICEPTIN; OPIATE PEPTIDE; PARVALBUMIN; TETRAGASTRIN;

ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; FEAR; FREEZING; GENE OVEREXPRESSION; GENOTYPE; HUMAN; IMMUNOREACTIVITY; LEARNING; NONHUMAN; PANIC; PARAVENTRICULAR THALAMIC NUCLEUS; PASSIVE AVOIDANCE; PERIAQUEDUCTAL GRAY MATTER; PONS RETICULAR FORMATION; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SENSORY GATING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANXIETY; BRAIN; CHOLECYSTOKININ; FEAR; HUMANS; NEUROPEPTIDE Y; OPIOID PEPTIDES;

EID: 84870704141     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2012.03.004     Document Type: Article

References (133)

1. Jovanovic T., Ressler K.J. How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. Am J Psychiatry 2010, 167:648-662.
2. Quirk G.J., Pare D., Richardson R., Herry C., Monfils M.H., et al. Erasing fear memories with extinction training. J Neurosci 2010, 30:14993-14997.
3. Goosens K.A. Hippocampal regulation of aversive memories. Curr Opin Neurobiol 2011, 21:460-466.
4. Quirk G.J., Garcia R., Gonzalez-Lima F. Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiatry 2006, 60:337-343.
5. Vertes R.P. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 2004, 51:32-58.
6. Myers K.M., Davis M. Mechanisms of fear extinction. Mol Psychiatry 2007, 12:120-150.
7. Hughes J., Kosterlitz H.W. Opioid Peptides: introduction. Br Med Bull 1983, 39:1-3.
8. Waldhoer M., Bartlett S.E., Whistler J.L. Opioid receptors. Annu Rev Biochem 2004, 73:953-990.
9. Fanselow M.S., Bolles R.C. Naloxone and shock-elicited freezing in the rat. J Comp Physiol Psychol 1979, 93:736-744.
10. Erhman R.N., Josephson J., Schull J., Sparich C. An assessment of the behavioral effects of the endorphin system with instrumental and classical conditioning paradigms. Paper presented at the meeting of the Eastern Psychological Association New York 1979.
11. Fanselow M.S. Naloxone and Pavlovian fear conditioning. Learn Motiv 1981, 12:398-419.
12. Fanselow M.S., Kim J.J., Young S.L., Calcagnetti D.J., DeCola J.P., et al. Differential effects of selective opioid peptide antagonists on the acquisition of pavlovian fear conditioning. Peptides 1991, 12:1033-1037.
13. Sanders M.J., Kieffer B.L., Fanselow M.S. Deletion of the mu opioid receptor results in impaired acquisition of Pavlovian context fear. Neurobiol Learn Mem 2005, 84:33-41.
14. McNally G.P., Westbrook R.F. Opioid receptors regulate the extinction of Pavlovian fear conditioning. Behav Neurosci 2003, 117:1292-1301.
15. McNally G.P., Pigg M., Weidemann G. Blocking, unblocking, and overexpectation of fear: a role for opioid receptors in the regulation of Pavlovian association formation. Behav Neurosci 2004, 118:111-120.
16. Rescorla R.A., Wagner A.R. A Theory of Pavlovian Conditioning: Variations in the Effectiveness of Reinforcement and Nonreinforcement 1972, Appleton-Century-Crofts, New York.
17. Mackintosh N.J., Reese B. One-Trial Overshadowing. Q J Exp Psychol 1979, 31:519-526.
18. Zelikowsky M., Fanselow M.S. Opioid regulation of Pavlovian overshadowing in fear conditioning. Behav Neurosci 2010, 124:510-519.
19. McNally G.P., Pigg M., Weidemann G. Opioid receptors in the midbrain periaqueductal gray regulate extinction of pavlovian fear conditioning. J Neurosci 2004, 24:6912-6919.
20. Carrive P. The periaqueductal gray and defensive behavior: functional representation and neuronal organization. Behav Brain Res 1993, 58:27-47.
21. McNally G.P., Lee B.W., Chiem J.Y., Choi E.A. The midbrain periaqueductal gray and fear extinction: opioid receptor subtype and roles of cyclic AMP, protein kinase A, and mitogen-activated protein kinase. Behav Neurosci 2005, 119:1023-1033.
22. McNally G.P. Facilitation of fear extinction by midbrain periaqueductal gray infusions of RB101(S), an inhibitor of enkephalin-degrading enzymes. Behav Neurosci 2005, 119:1672-1677.
23. Egan K.J., Carr J.E., Hunt D.D., Adamson R. Endogenous opiate system and systematic desensitization. J Consult Clin Psychol 1988, 56:287-291.
24. Arntz A., Merckelbach H., de Jong P. Opioid antagonist affects behavioral effects of exposure in vivo. J Consult Clin Psychol 1993, 61:865-870.
25. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995, 377:532-535.
26. Roozendaal B., Lengvilas R., McGaugh J.L., Civelli O., Reinscheid R.K. Orphanin FQ/nociceptin interacts with the basolateral amygdala noradrenergic system in memory consolidation. Learn Mem 2007, 14:29-35.
27. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., et al. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 1998, 394:577-581.
28. Higgins G.A., Kew J.N., Richards J.G., Takeshima H., Jenck F., et al. A combined pharmacological and genetic approach to investigate the role of orphanin FQ in learning and memory. Eur J Neurosci 2002, 15:911-922.
29. Fornari R.V., Soares J.C., Ferreira T.L., Moreira K.M., Oliveira M.G. Effects of nociceptin/orphanin FQ in the acquisition of contextual and tone fear conditioning in rats. Behav Neurosci 2008, 122:98-106.
30. Knoll A.T., Meloni E.G., Thomas J.B., Carroll F.I., Carlezon W.A. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007, 323:838-845.
31. Knoll A.T., Muschamp J.W., Sillivan S.E., Ferguson D., Dietz D.M., et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 2011, 70:425-433.
32. Vanderhaeghen J.J., Signeau J.C., Gepts W. New peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature 1975, 257:604-605.
33. Rehfeld J.F. Neuronal cholecystokinin: one or multiple transmitters?. J Neurochem 1985, 44:1-10.
34. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 1994, 49:133-141.
35. Hill D.R., Campbell N.J., Shaw T.M., Woodruff G.N. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 1987, 7:2967-2976.
36. Mercer L.D., Beart P.M. Immunolocalization of CCK1R in rat brain using a new anti-peptide antibody. Neurosci Lett 2004, 359:109-113.
37. Lotti V.J., Chang R.S. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989, 162:273-280.
38. Schafer U., Harhammer R., Boomgaarden M., Sohr R., Ott T., et al. Binding of cholecystokinin-8 (CCK-8) peptide derivatives to CCKA and CCKB receptors. J Neurochem 1994, 62:1426-1431.
39. Fink H., Rex A., Voits M., Voigt J.P. Major biological actions of CCK-a critical evaluation of research findings. Exp Brain Res 1998, 123:77-83.
40. Fekete M., Lengyel A., Hegedus B., Penke B., Zarandy M., et al. Further analysis of the effects of cholecystokinin octapeptides on avoidance behaviour in rats. Eur J Pharmacol 1984, 98:79-91.
41. Kadar T., Fekete M., Telegdy G. Modulation of passive avoidance behaviour of rats by intracerebroventricular administration of cholecystokinin octapeptide sulfate ester and nonsulfated cholecystokinin octapeptide. Acta Physiol Acad Sci Hung 1981, 58:269-274.
42. Hadjiivanova C., Belcheva S., Belcheva I. Cholecystokinin and learning and memory processes. Acta Physiol Pharmacol Bulg 2003, 27:83-88.
43. Wang H., Wong P.T., Spiess J., Zhu Y.Z. Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Neurosci Biobehav Rev 2005, 29:1361-1373.
44. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 1989, 46:511-517.
45. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 1991, 48:603-610.
46. Bradwejn J., Koszycki D., Couetoux du Tertre A., van Megen H., den Boer J., et al. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994, 51:486-493.
47. Abelson J.L., Nesse R.M. Cholecystokinin-4 and panic. Arch Gen Psychiatry 1990, 47:395.
48. Benkelfat C., Bradwejn J., Meyer E., Ellenbogen M., Milot S., et al. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry 1995, 152:1180-1184.
49. Javanmard M., Shlik J., Kennedy S.H., Vaccarino F.J., Houle S., et al. Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry 1999, 45:872-882.
50. Kennedy J.L., Bradwejn J., Koszycki D., King N., Crowe R., et al. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 1999, 4:284-285.
51. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
52. Muinos-Gimeno M., Espinosa-Parrilla Y., Guidi M., Kagerbauer B., Sipila T., et al. Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. Biol Psychiatry 2011, 69:526-533.
53. Fendt M., Koch M., Kungel M., Schnitzler H.U. Cholecystokinin enhances the acoustic startle response in rats. Neuroreport 1995, 6:2081-2084.
54. Davis M., Gendelman D.S., Tischler M.D., Gendelman P.M. A primary acoustic startle circuit: lesion and stimulation studies. J Neurosci 1982, 2:791-805.
55. Josselyn S.A., Frankland P.W., Petrisano S., Bush D.E., Yeomans J.S., et al. The CCKB antagonist, L-365,260, attenuates fear-potentiated startle. Peptides 1995, 16:1313-1315.
56. Frankland P.W., Josselyn S.A., Bradwejn J., Vaccarino F.J., Yeomans J.S. Intracerebroventricular infusion of the CCKB receptor agonist pentagastrin potentiates acoustic startle. Brain Res 1996, 733:129-132.
57. Frankland P.W., Josselyn S.A., Bradwejn J., Vaccarino F.J., Yeomans J.S. Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci 1997, 17:1838-1847.
58. Chhatwal J.P., Gutman A.R., Maguschak K.A., Bowser M.E., Yang Y., et al. Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology 2009, 34:509-521.
59. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
60. Mascagni F., McDonald A.J. Immunohistochemical characterization of cholecystokinin containing neurons in the rat basolateral amygdala. Brain Res 2003, 976:171-184.
61. Wunderlich G.R., Raymond R., DeSousa N.J., Nobrega J.N., Vaccarino F.J. Decreased CCK(B) receptor binding in rat amygdala in animals demonstrating greater anxiety-like behavior. Psychopharmacology (Berl) 2002, 164:193-199.
62. Harro J., Kiivet R.A., Lang A., Vasar E. Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 1990, 39:63-71.
63. Vasar E., Peuranen E., Harro J., Lang A., Oreland L., et al. Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein. Naunyn Schmiedebergs Arch Pharmacol 1993, 348:96-101.
64. Koks S., Vasar E., Soosaar A., Lang A., Volke V., et al. Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol 1997, 7:289-294.
65. Izumi T., Inoue T., Tsuchiya K., Hashimoto S., Ohmori T., et al. Effect of the selective CCKB receptor antagonist LY288513 on conditioned fear stress in rats. Eur J Pharmacol 1996, 300:25-31.
66. Tsutsumi T., Akiyoshi J., Isogawa K., Kohno Y., Hikichi T., et al. Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158. Neuropeptides 1999, 33:483-486.
67. Tsutsumi T., Akiyoshi J., Hikichi T., Kiyota A., Kohno Y., et al. Suppression of conditioned fear by administration of CCKB receptor antisense oligodeoxynucleotide into the lateral ventricle. Pharmacopsychiatry 2001, 34:232-237.
68. Raud S., Innos J., Abramov U., Reimets A., Koks S., et al. Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 2005, 181:347-357.
69. Chen Q., Nakajima A., Meacham C., Tang Y.P. Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse. Proc Natl Acad Sci U S A 2006, 103:3881-3886.
70. Chen Q., Tang M., Mamiya T., Im H.I., Xiong X., et al. Bi-directional effect of cholecystokinin receptor-2 overexpression on stress-triggered fear memory and anxiety in the mouse. PLoS One 2010, 5:e15999.
71. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
72. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., et al. Neuropeptide Y distribution in the rat brain. Science 1983, 221:877-879.
73. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rossor M.N., et al. Neuropeptide Y distribution in human brain. Nature 1983, 306:584-586.
74. Chronwall B.M., DiMaggio D.A., Massari V.J., Pickel V.M., Ruggiero D.A., et al. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 1985, 15:1159-1181.
75. Morris B.J. Neuronal localisation of neuropeptide Y gene expression in rat brain. J Comp Neurol 1989, 290:358-368.
76. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci 2006, 361:1159-1185.
77. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007, 13:803-811.
78. Haas D.A., George S.R. Neuropeptide Y-induced effects on hypothalamic corticotropin-releasing factor content and release are dependent on noradrenergic/adrenergic neurotransmission. Brain Res 1989, 498:333-338.
79. Hanson E.S., Dallman M.F. Neuropeptide Y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995, 7:273-279.
80. White B.D., Dean R.G., Edwards G.L., Martin R.J. Type II corticosteroid receptor stimulation increases NPY gene expression in basomedial hypothalamus of rats. Am J Physiol 1994, 266:R1523-R1529.
81. King P.J., Widdowson P.S., Doods H.N., Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem 1999, 73:641-646.
82. Pomonis J.D., Levine A.S., Billington C.J. Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade of neuropeptide Y-induced feeding revealed by c-fos expression. J Neurosci 1997, 17:5175-5182.
83. Yannielli P.C., Harrington M.E. Neuropeptide Y in the mammalian circadian system: effects on light-induced circadian responses. Peptides 2001, 22:547-556.
84. Baraban S.C. Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides 2004, 38:261-265.
85. Thiele T.E., Sparta D.R., Hayes D.M., Fee J.R. A role for neuropeptide Y in neurobiological responses to ethanol and drugs of abuse. Neuropeptides 2004, 38:235-243.
86. Kalra S.P., Kalra P.S. NPY-an endearing journey in search of a neurochemical on/off switch for appetite, sex and reproduction. Peptides 2004, 25:465-471.
87. Groneberg D.A., Folkerts G., Peiser C., Chung K.F., Fischer A. Neuropeptide Y (NPY). Pulm Pharmacol Ther 2004, 17:173-180.
88. Silva A.P., Xapelli S., Grouzmann E., Cavadas C. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr Drug Targets CNS Neurol Disord 2005, 4:331-347.
89. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
90. Wahlestedt C., Reis D.J. Neuropeptide Y-related peptides and their receptors-are the receptors potential therapeutic drug targets?. Annu Rev Pharmacol Toxicol 1993, 33:309-352.
91. Michel M.C., Lewejohann K., Farke W., Bischoff A., Feth F., et al. Regulation of NPY/NPY Y1 receptor/G protein system in rat brain cortex. Am J Physiol 1995, 268:R192-R200.
92. Lindner D., Stichel J., Beck-Sickinger A.G. Molecular recognition of the NPY hormone family by their receptors. Nutrition 2008, 24:907-917.
93. Dumont Y., Fournier A., St-Pierre S., Quirion R. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci 1993, 13:73-86.
94. Walter A., Mai J.K., Jimenez-Hartel W. Mapping of neuropeptide Y-like immunoreactivity in the human forebrain. Brain Res Bull 1990, 24:297-311.
95. Caberlotto L., Fuxe K., Hurd Y.L. Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. J Chem Neuroanat 2000, 20:327-337.
96. Parker R.M., Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 1999, 11:1431-1448.
97. Wolak M.L., DeJoseph M.R., Cator A.D., Mokashi A.S., Brownfield M.S., et al. Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry. J Comp Neurol 2003, 464:285-311.
98. Rostkowski A.B., Teppen T.L., Peterson D.A., Urban J.H. Cell-specific expression of neuropeptide Y Y1 receptor immunoreactivity in the rat basolateral amygdala. J Comp Neurol 2009, 517:166-176.
99. Flood J.F., Baker M.L., Hernandez E.N., Morley J.E. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res 1989, 503:73-82.
100. Heilig M., McLeod S., Koob G.K., Britton K.T. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 1992, 41:61-69.
101. Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept 1995, 59:201-205.
102. Broqua P., Wettstein J.G., Rocher M.N., Gauthier-Martin B., Junien J.L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 1995, 6:215-222.
103. Britton K.T., Southerland S., Van Uden E., Kirby D., Rivier J., et al. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl) 1997, 132:6-13.
104. Sajdyk T.J., Vandergriff M.G., Gehlert D.R. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol 1999, 368:143-147.
105. Kokare D.M., Dandekar M.P., Chopde C.T., Subhedar N. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats. Brain Res 2005, 1043:107-114.
106. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 1989, 98:524-529.
107. Kask A., Kivastik T., Rago L., Harro J. Neuropeptide Y Y1 receptor antagonist BIBP3226 produces conditioned place aversion in rats. Prog Neuropsychopharmacol Biol Psychiatry 1999, 23:705-711.
108. Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Rudolf K., et al. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 1995, 275:143-149.
109. Primeaux S.D., Wilson S.P., Cusick M.C., York D.A., Wilson M.A. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology 2005, 30:1589-1597.
110. Sajdyk T.J., Schober D.A., Gehlert D.R. Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology 2002, 43:1165-1172.
111. Sajdyk T.J., Schober D.A., Smiley D.L., Gehlert D.R. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav 2002, 71:419-423.
112. Sajdyk T.J., Johnson P.L., Leitermann R.J., Fitz S.D., Dietrich A., et al. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J Neurosci 2008, 28:893-903.
113. Thorsell A., Carlsson K., Ekman R., Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 1999, 10:3003-3007.
114. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci U S A 2000, 97:12852-12857.
115. McGuire J.L., Larke L.E., Sallee F.R., Herman J.P., Sah R. Differential Regulation of Neuropeptide Y in the Amygdala and Prefrontal Cortex during Recovery from Chronic Variable Stress. Front Behav Neurosci 2011, 5:54.
116. Nakajima M., Inui A., Teranishi A., Miura M., Hirosue Y., et al. Effects of pancreatic polypeptide family peptides on feeding and learning behavior in mice. J Pharmacol Exp Ther 1994, 268:1010-1014.
117. Redrobe J.P., Dumont Y., Herzog H., Quirion R. Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci 2004, 22:159-166.
118. McDonald A.J., Pearson J.C. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci Lett 1989, 100:53-58.
119. Tovote P., Meyer M., Beck-Sickinger A.G., von Horsten S., Ove Ogren S., et al. Central NPY receptor-mediated alteration of heart rate dynamics in mice during expression of fear conditioned to an auditory cue. Regul Pept 2004, 120:205-214.
120. Karlsson R.M., Holmes A., Heilig M., Crawley J.N. Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice. Pharmacol Biochem Behav 2005, 80:427-436.
121. Gutman A.R., Yang Y., Ressler K.J., Davis M. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J Neurosci 2008, 28:12682-12690.
122. Krysiak R., Obuchowicz E., Herman Z.S. Conditioned fear-induced changes in neuropeptide Y-like immunoreactivity in rats: the effect of diazepam and buspirone. Neuropeptides 2000, 34:148-157.
123. Pickens C.L., Adams-Deutsch T., Nair S.G., Navarre B.M., Heilig M., et al. Effect of pharmacological manipulations of neuropeptide Y and corticotropin-releasing factor neurotransmission on incubation of conditioned fear. Neuroscience 2009, 164:1398-1406.
124. Fendt M., Burki H., Imobersteg S., Lingenhohl K., McAllister K.H., et al. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology (Berl) 2009, 206:291-301.
125. Verma D., Tasan R.O., Mietzsch M., Weger S., Heilbronn R., Herzog H., et al. Reduced fear conditioning after viral vector mediated neuropeptide Y administration into the basolateral amygdala. BMC Pharmacol 2011, 11.
126. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 2004, 38:113-121.
127. Rasmusson A.M., Hauger R.L., Morgan C.A., Bremner J.D., Charney D.S., et al. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol Psychiatry 2000, 47:526-539.
128. Mickey B.J., Zhou Z., Heitzeg M.M., Heinz E., Hodgkinson C.A., et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 2011, 68:158-166.
129. Morgan C.A., Wang S., Southwick S.M., Rasmusson A., Hazlett G., et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry 2000, 47:902-909.
130. Yehuda R., Brand S., Yang R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol Psychiatry 2006, 59:660-663.
131. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008, 63:1118-1126.
132. Walker D.L., Ressler K.J., Lu K.T., Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002, 22:2343-2351.
133. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004, 61:1136-1144.